Investor Relations

We have developed this Investor Relations section to provide our investors (both existing and potential) and our other financial stakeholders with comprehensive, detailed and up to the minute information.

IR-related PDF documents

Syntopix One Page Summary July 2008
Proposed Placing of 2,000,756 New Ordinary Shares July 2008
Syntopix Admission Document 2006
Articles of Association 2005

Current share price

View further details on the LSE website here >>

Financial calendar

2008

• 24 April 2008 - Interim results 2008
• 20 October 2008 - Preliminary results 2008
• 8 December 2008 - Annual General Meeting

2007

• 19 April 2007 - Interim results 2007
• 18 October 2007 - Preliminary results 2007
• 12 December 2007 - Annual General Meeting

2006

• 28 September 2006 - Preliminary results 2006
• 12 December 2006 - Annual General Meeting

Significant shareholders (over 3%)

as at 22nd October 2008

Shareholder	No. of Shares	%
IP2IPO Limited (together with Techtran Group Limited)	1,446,832	18.75%
The Wellcome Trust Limited	519,168	6.73%
Invesco Perpetual	492,656	6.38%
Pershing Keen Nominees Limited	470,371	6.09%
IP Venture Fund Limited	425,977	5.52%
The University of Leeds	390,000	5.05%
Credit Suisse Client Nominees (UK) Limited	380,000	4.92%
Ridings Early Growth Investment Company Limited	322,109	4.17%
Peter Ariowitsch	266,667	3.46%
Dr Jon Cove	266,180	3.45%
Dr Anne Eady	266,180	3.45%
	5,246,140	67.98%
Others	2,471,691	32.02%
Total issued share capital	7,717,831	100.00%

The percentage of shares not in public hands is 40.85%.

Investor relations contact

For all information about Syntopix please contact:

Dr. Stephen P. Jones - Chief Executive Officer
Email: spj@syntopix.com
Tel. +44 (0) 845 125 9204

Syntopix is located at:

Syntopix Group plc
The Institute of Pharmaceutical Innovation
University of Bradford
Bradford
BD7 1DP

Last updated: 27/11/2008

COPYRIGHT 2009 SYNTOPIX GROUP PLC, SYNTOPIX IS A REGISTERED TRADEMARK ACCESSIBILITY STATEMENT SITE MAP TEXT ONLY VERSION TERMS & CONDITIONS